iwCLL 2021: Long term results of a study examining umbralisib, ublituximab and pembrolizumab for treatment of relapsed chronic lymphocytic leukemia.
Home / Resource Library / U2 Plus Pembrolizumab Shows Continued Efficacy at 5 Years in CLL and Richters Transformation